Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% Higher – Still a Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price was up 5.6% during mid-day trading on Thursday . The company traded as high as $29.87 and last traded at $29.84. Approximately 85,014 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 797,037 shares. The stock had previously closed at $28.25.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GPCR shares. Morgan Stanley began coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities restated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $86.50.

Structure Therapeutics Stock Performance

The firm’s fifty day moving average is $34.78 and its 200 day moving average is $38.19. The firm has a market cap of $1.73 billion, a P/E ratio of -40.93 and a beta of -3.41.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently made changes to their positions in GPCR. Principal Financial Group Inc. bought a new position in Structure Therapeutics in the 2nd quarter valued at about $6,489,000. Natixis Advisors LLC lifted its position in shares of Structure Therapeutics by 29.4% during the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock valued at $746,000 after acquiring an additional 4,321 shares during the period. Gilbert & Cook Inc. bought a new position in Structure Therapeutics during the second quarter worth $229,000. TD Asset Management Inc increased its stake in Structure Therapeutics by 47.9% in the second quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock valued at $8,309,000 after purchasing an additional 68,490 shares in the last quarter. Finally, Pier Capital LLC boosted its position in shares of Structure Therapeutics by 3.7% during the 2nd quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock worth $3,974,000 after purchasing an additional 3,647 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.